Impala Nordic has published an equity analysis on Brain+ A/S (“Brain+” or “the Company”), a Danish life-science innovator pioneering digital solutions for improved dementia care.

Brain+ is developing Ayla, the world’s first dementia-care platform. The company’s flagship product, Ayla – Your CST Assistant, was launched in Denmark and the UK in the second half of 2024 (H2 2024).

Ayla provides an effective and scalable solution for delivering CST (Cognitive Stimulation Therapy), a proven and recommended non-drug dementia therapy designed to maintain and enhance cognitive abilities such as memory, language skills, problem-solving, orientation, and social interaction.

The Company aims to achieve operational break-even by mid-2026, supported by a recently completed warrants transaction that secured gross proceeds of DKK 5.9 million.

Click here to read the full analysis.